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Expression of ZIC family genes in meningiomas








Background: Zic zinc finger proteins are present in the developing rodent meninges and are required for cell
proliferation and differentiation of meningeal progenitors. Although human ZIC genes are known to be molecular
markers for medulloblastomas, their expression in meningioma has not been addressed to date.
Methods: We examined the mRNA and protein expression of human ZIC1, ZIC2, ZIC3, ZIC4 and ZIC5 genes in
meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and
immunostaining.
Results: ZIC1, ZIC2 and ZIC5 transcript levels in meningiomas were higher than those in whole brain or normal
dura mater, whereas all five ZIC genes were abundantly expressed in medulloblastomas. The expression level of
ZIC1 in public microarray data was greater in meningiomas classified as World Health Organization Grade II
(atypical) than those classified as Grade I (benign). Immunoscreening using anti-ZIC antibodies revealed that 23 out
of 23 meningioma cases were ZIC1/2/3/5-immunopositive. By comparison, nuclear staining by the anti-ZIC4
antibody was not observed in any meningioma case, but was strongly detected in all four medulloblastomas. ZIC-
positive meningiomas included meningothelial, fibrous, transitional, and psammomatous histological subtypes. In
normal meninges, ZIC-like immunoreactivities were detected in vimentin-expressing arachnoid cells both in human
and mouse.
Conclusions: ZIC1, ZIC2, and ZIC5 are novel molecular markers for meningiomas whereas ZIC4 expression is highly
selective for medulloblastomas. The pattern of ZIC expression in both of these tumor types may reflect the
properties of the tissues from which the tumors are derived.
Background
Meningiomas are primary central nervous system
tumors derived from arachnoidal (meningothelial) cells
[reviewed in [1-3]]. Meningiomas are the most common
type of benign intracranial brain tumor, with an annual
incidence of approximately 2.3 to 6 per 100,000 persons
[1]. They are classified into three World Health Organi-
zation (WHO) grades: benign (Grade I), atypical (Grade
II), and malignant (Grade III) [1] based on the degree of
anaplasia, number of mitoses, and presence of necrosis
[1,3]. Grade I, II and III meningiomas account for
approximately 80%, 5% to 20%, and 1% to 2% of all
meningiomas, respectively [1]. Further classification is
possible based on histopathological types; for example,
Grade I tumors include meningiothelial, fibrous,
transitional (mixed), psammomatous, angiomatous, and
secretory meningiomas [1]. Clinicopathological examina-
tion of meningioma has benefited from the discovery of
several molecular markers such as vimentin and epithe-
lial membrane antigen (EMA) [1]. The presence of these
molecules in meningiomas may partly reflect the cellular
properties of arachnoidal cap cells from which menin-
giomas are thought to derive.
Recently, Inoue et al. [4] revealed that developing
meningeal cells in mouse produce Zic family zinc finger
proteins. Zic proteins are known to play critical roles in
animal development [reviewed in [5]]. In humans, muta-
tions in ZIC genes are associated with congenital
anomalies such as holoprosencephaly (medial forebrain
dysgenesis), heterotaxy (left-right axis disturbance), and
Dandy-Walker malformation (cerebellar dysgenesis)
[reviewed in [5,6]]. In meningeal cell development,
mouse Zic proteins are present in the primitive meninx
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Zic1/Zic3 results in impaired proliferation and differen-
tiation of meningeal precursors [4]. These findings led
us to hypothesize that ZIC proteins are present in
meningiomas.
Previous studies have reported immunoreactivities to
ZIC proteins in medulloblastoma, another type of
brain tumor. ZIC1 is predominantly expressed in
medulloblastoma [7,8], and ZIC2 expression is down-
regulated in medulloblastoma compared to its mRNA
level in normal cerebellum [9]. In normal tissue, ZIC1
is preferentially expressed in cerebellar granule neu-
rons and their progenitors [8]. The abundance of the
ZIC1 protein in medulloblastoma is considered to
reflect the properties of the cell of origin, cerebellar
granule neuron. However, the expression of the other
ZIC genes (ZIC2, ZIC3, ZIC4,a n dZIC5)h a sn o tb e e n
investigated in medulloblastoma or other brain tumors.
A comparison of the expression of ZIC family mem-
bers is required. But current studies are limited by the
structural similarities and the cross-reactivity of the
antibodies [10].
These observations led us to investigate the expression
profiles of ZIC genes in brain tumors, focusing on
meningiomas. We first examined the levels of ZIC1-5
mRNAs in various brain tumors. Then ZIC-like immu-
noreactivity was examined in meningiomas and other
brain tumors. Our results indicate that the expression of
ZIC1, ZIC2 and ZIC5 is a conserved feature of
meningioma.
Methods
Human materials and animals
All sampling procedures for human brain tumors were
performed according to the Ethics Guidelines for
Human Genome/Gene Analysis Research published by
the Japanese Ministry of Education, Culture, Sports,
Science and Technology http://www.lifescience.mext.go.
jp/files/pdf/40_213.pdf. C57BL/6J mice were purchased
from Nihon SLC (Shizuoka, Japan). Animal experiments
were approved by the Animal Experiment Committee of
the RIKEN Brain Science Institute.
RNA isolation and RT-PCR analysis
RNA samples were prepared from human brain tumors
using TRIZOL (Invitrogen, Carlsbad, CA, USA). Total
RNA from human whole brain, liver, lung, kidney, and
kidney tumor was purchased from Clontech (Mountain
View, CA, USA). All RNA samples were treated with
RNase-free DNase I (Promega, Madison, WI, USA) before
the reverse transcription reaction. Reverse transcription
and PCR were performed using ThermoScript reverse
transcriptase (Invitrogen) and TaKaRa Ex Taq Hot Start
Version (TAKARA BIO, Shiga Japan), respectively. The
accession numbers, primer sequences, the size of PCR
products, and number of PCR cycles were as follows: ZIC1
(NM_003412), 5’-GGCCCGGAGCAGAGTAAT-3’ and 5’-
AGCCCTCAAACTCGCACTT-3’ (229 bp, 26 cycles);
ZIC2 (NM_007129), 5’-CCCTTCAAGGCCAAATACAA-
3’ and 5’-TGCATGTGCTTCTTCCTGTC-3’ (218 bp, 26
cycles); ZIC3 (NM_003413), 5’-GCAAGTCTTTCA
AGGCGAAG-3’ and 5’-CATGCATGTGCTTCTTAC
GG-3’ (225 bp, 28 cycles); ZIC4 (NM_032153), 5’-GCC
CTTCAAAGCCAAATACA-3’ and 5’-GCCCTCGAAC
TCGCATC-3’ (172 bp, 28 cycles); ZIC5 (NM_033132), 5’-
TCTGCTTCTGGGAGGACTGT-3’ and 5’-GGGAATGT
TTCTTCCGATCA-3’ (252 bp, 28 cycles); and ACTB
(NM_001101), 5’-CAACCGCGAGAAGATGACC-3’ and
5’-TCCAGGGCGACATAGCACA-3’ (324 bp, 22 cycles).
Each PCR cycle consisted of 1 min at 94°C, 30 s at 62.5°C,
and 1 min at 72°C. RT-PCR product was harvested during
the log-linear phase of the amplification curve at the PCR
cycles indicated above. The PCR products were separated
by electrophoresis in a 2.0% agarose gel and quantified by
densitometry of ethidium bromide-stained bands using
ImageJ version 1.33 http://rsb.info.nih.gov/ij/. The tran-
script amounts were normalized to ACTB. The results are
indicated as relative values to the transcript amount in
whole brain total RNA. The means of the three indepen-
dent RT-PCR experiments are indicated. The absence of
amplified products in RNA samples that had not been
reverse transcribed was confirmed at the cycles indicated
(data not shown).
Analysis of public microarray data
The meningioma microarray results of Keller et al. [11]
were obtained from the Gene Expression Omnibus
(GEO) repository ftp://ftp.ncbi.nih.gov/pub/geo/DATA/
supplementary/series/GSE12530/GSE12530_RAW.tar;
the data included 24 meningioma and two dura mater
controls profiled on GE Healthcare/Amersham Bios-
ciences CodeLink Human Whole Genome Bioarrays.
Following probes (ID_REF) were subjected for the analy-
sis: ZIC1, 228079; ZIC2, 56068; ZIC3, 387012; ZIC4,
456009; ZIC5, 80028. For each gene, expression level in
meningioma was indicated relative to the expression
level in normal dura mater.
Protein immunoblots and immunohistochemistry
Human ZIC1-5 expression plasmid vectors were con-
structed in pcDNA3.1 vector (Invitrogen) that had been
modified to contain three tandem hemagglutinin (HA)
epitope tag-encoding sequences. The open reading
frame sequences were obtained by PCR amplification of
a human brain cDNA (Clontech) and a BAC clone
(RP11-1148D4, BACPAC Resources Center, CHORI,
Oakland, CA, USA) and subsequent reconstruction of
the sequence-verified fragments.
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cells or 293T cells using TransIT-LT1 transfection
reagent (Mirus, Madison, WI, USA). For protein immu-
noblot, the transfected cells were lysed in sodium dode-
cyl sulfate - polyacrylamide gel electrophoresis (SDS-
PAGE) loading buffer. The proteins were separated by
SDS-PAGE and transferred to polyvinylidene di?uoride
membranes. The membranes were first incubated with
5% skim milk in phosphate-buffered saline (PBS) con-
taining 0.1% Tween20 (PBST) for 1 h to block non-spe-
cific binding, and then incubated with either rat
monoclonal anti-HA tag antibody (3F10, 1:4000), rabbit
polyclonal anti-Zic2 antibody [CXY2, [12]], mouse
monoclonal anti-Zic1 antibody [ZC26, [8]], or rabbit
polyclonal anti-ZIC4 antibody (ProteinTech Group, Chi-
cago, IL, USA) diluted in the blocking buffer, at 4°C
overnight. Membranes were then washed in PBST for 1
h, and incubated for 1 h with horseradish peroxidase-
conjugated anti-rabbit, anti-rat, or anti-mouse antibodies
(Jackson ImmunoResearch Laboratories, West Grove,
PA, USA). After re-washing with PBST, the bound anti-
bodies were detected using enhanced chemilumines-
cence Western blot detection reagent (GE Healthcare,
Buckinghamshire, UK).
Immunofluorescence staining was performed as
described previously [4,13]. Immunohistochemical stain-
ing of human brain tumor specimen was performed as
described [8] and briefly described below. Formalde-
hyde-fixed, paraffin embedded sections (3 to 6 μm) were
prepared using a standard procedure [8]. The antigen
retrieval was performed by autoclaving the dewaxed,
hydrated tissue specimens in 10 mM sodium citrate (pH
6.5) at 121°C for 5 min. The sections were further incu-
bated in 0.3% hydrogen peroxide for 10 min to inacti-
vate the endogenous peroxidase-like activity. Blocking of
non-specific binding was performed by immersing the
specimens in a PBST containing 1% skim milk and 2%
normal goat serum for 30 min at room temperature.
The primary antibodies used in the immunohistochem-
ical staining were anti-ZIC (CXY2, ZC26, and anti-
ZIC4) anti-vimentin (Nichirei Biosciences, Tokyo,
Japan), anti-EMA (Dako, Glostrup, Denmark), and anti-
chondroitin sulfate proteoglycan (CS56, Sigma-Aldrich,
St. Louis, MO, USA).
The sections were incubated at 4°C overnight in
blocking buffer containing appropriately diluted primary
antibodies (CXY2, 1:2000; ZC26, 1:500; anti-ZIC4, 1:400;
anti-vimentin, 1:300; anti-EMA, 1:4). The bound primary
antibodies were detected by immunoperoxidase reaction
using VECTASTAIN Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA) and 3,3’-Diaminobenzidine
(DAB) as a substrate. The double labeling was carried
out by sequential primary antibody incubation and
detection using two different chromogens, DAB and
DAB-Nickel. Digital images were obtained using the
NanoZoomer Digital Pathology C9600 (Hamamatsu
Photonics, Shizuoka, Japan) image scanner and analyzed
using the NDPViewer software (Hamamatsu Photonics).
Results
Expression of ZIC1-5 in various types of brain tumors
We first examined the mRNA levels of the five ZIC
genes in various types of brain tumors including astro-
cytoma, oligodendroglioma, glioblastoma, medulloblas-
toma, primitive neuroectodermal tumor, ganglioglioma,
neurinoma, subependymoma, and meningioma (Figure
1, Table 1). A semi-quantitative RT-PCR analysis was
performed using ZIC gene specific primer sets and
cDNA synthesized from brain tumor RNA. The most
consistent feature of ZIC expression was the high level
of all five ZIC transcripts in the three medulloblastoma
cases, when compared to their level in whole brain; the
relative amounts varied from 2- to 3-fold for ZIC1 to
40- to 70-fold for ZIC4. In the three meningioma cases,
the ZIC1, ZIC2 and ZIC5 mRNA levels were 2- to 3.5-
fold, 2- to 4.7- fold, and 3- to 8-fold higher, respectively,
than those in the whole brain. The ZIC3 and ZIC4
mRNA levels were higher in meningioma than in whole
brain in one out of the three cases.
Expression of ZIC1-5 in meningioma with different
histological grades
We next evaluated ZIC1-5 mRNA levels in meningioma
of various histological grades. For this purpose, we uti-
lized a recent study in which a total of 24 meningioma
cases and two normal dura mater tissue samples were
subjected to microarray analysis [11]; the cases com-
prised eight benign (WHO Grade I), eight atypical
(WHO Grade II) and eight malignant (WHO Grade III)
tumors. For each ZIC gene, the mRNA level in menin-
gioma relative to the level in normal dura mater was
deduced from the published data (Figure 2). The mRNA
levels of ZIC1, ZIC2 and ZIC5 were higher in menin-
gioma than in dura mater. ZIC1 levels were significantly
higher in Grade II tumors (5.0 fold) than in Grade I
tumors (1.7 fold) (P = 0.027, Welch’s t-test).
Immunoscreening of ZIC proteins in brain
tumor specimens
For the immunohistochemical detection of human ZIC
proteins, we used three anti-ZIC antibodies. Anti-Zic2
polyclonal antibody (CXY2) and anti-Zic1 monoclonal
antibody (ZC26) recognize the C-terminal regions of
mouse Zic2 and Zic1, respectively. Anti-ZIC4 polyclonal
antibody was raised against a peptide corresponding to
human ZIC4 sequence. We first checked each antibody’s
specificity by protein immunoblot analysis (Figure 3)
and immunofluorescence staining (Additional file 1) of
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examined in the RT-PCR analysis
No. Age Gender Location Histological type
1 28 F Right frontal lobe Diffuse astrocytoma
2 43 F Right frontal lobe Gemistocytic astrocytoma
3 50 M Left frontal lobe Oligodendroglioma
4 67 F Bilateral frontal and
parietal lobes
Glioblastoma
5 57 M Left frontal lobe Glioblastoma
6 3 M Cerebellar vermis Medulloblastoma
7 12 M Cerebellar vermis Medulloblastoma
8 19 F Cerebellar hemisphere Medulloblastoma
9 30 M Right parietal lobe Supratentorial PNET
10 17 F Right temporal lobe Ganglioglioma
11 50 F Left cerebellopontine
angle
Vestibular neurinoma
12 70 M Left frontal lobe
(intraventricular)
Subependymoma
13 77 M ’Convexity’ Meningotheliomatous
meningioma
14 57 M ’Falx’ Fibrous meningioma
15 66 F ’Parasagittal’ Meningioma
16 58 F Right kidney Fuhrman grade II Renal
cell carcinoma
Figure 1 RT-PCR analysis of ZIC1–5 expression in normal tissue
and brain tumor tissue. (A) Representative photographs of
agarose gels showing RT-PCR products. (B) Relative amounts of ZIC
transcripts. The transcript amounts have been normalized to b actin
(ACTB) so that the value for the whole brain equals 1.0. Each bar
indicates the mean of three independent RT-PCR analyses. Error bars
indicate the standard error of the mean. Note that the graphs in (B)
indicate the relative transcript amount to those of brain. The relative
abundance among the five ZIC transcripts may be partly
represented by the difference in the band intensity in (A) together
with the PCR cycle and product size differences (See Methods).
Figure 2 The relative mRNA level of ZIC1–5 in meningioma
groups of different histological grades. The transcript levels were
deduced from a recent microarray analysis [11] that includes eight
each of Grade I (benign, open bar), Grade II (atypical, gray bar), and
Grade III (anaplastic, malignant, black bar) meningiomas. The
transcript levels in meningioma are indicated as relative to the level
in normal dura mater. Each bar indicates the mean of eight
independent tumor specimens. Error bars indicate the standard
error of the mean. The asterisks above bars indicate the statistical
significance of the difference between the meningioma classes and
the dura maters, and the asterisk above the bracket indicates that of
the ZIC1 expression difference between Grade I and Grade II
meningiomas. *, P < 0.05; **, P < 0.01; ***, P < 0.001 in Welch’s
t-test.
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produced in mammalian cells. In both assays, CXY2,
ZC26, and anti-ZIC4 recognized ZIC1/ZIC2/ZIC3/ZIC5,
ZIC1/ZIC2/ZIC3, and ZIC4, respectively. The combina-
torial use of these three antibodies was expected to
cover all five ZIC proteins.
We then applied these antibodies to the immunostaining
of paraffin-embedded brain tumor sections from
patients, in order to examine whether ZIC-like immu-
noreactivity is present in meningioma (Table 2). Both
CXY2 and ZC26 gave ZIC-like signals in the cell nuclei
of all 23 meningioma cases. The staining intensity was
generally higher for CXY2; but there was no obvious dif-
ference between CXY2 and ZC26 in terms of the distri-
bution of the signals across tissues (data not shown). By
contrast, anti-ZIC4 staining did not produce clear
nuclear staining in the meningioma cases. The anti-
ZIC4 antibody generated weak cytoplasmic staining in a
subset of cells (data not shown). We excluded the cyto-
plasmic staining from the current analysis because we
did not observe any obvious cytoplasmic localization of
epitope-tagged ZIC4 protein in cultured cells (Addi-
tional file 1). All three anti-ZIC antibodies gave clear
nuclear signals in the four medulloblastoma cases (Table
2), consistent with the RT-PCR results.
The histological subtypes of meningiomas included in
this study were meningothelial meningioma (Figure 4A,
B), fibrous meningioma (Figure 4C, D), transitional
(mixed) meningioma (Figure 4E, F), psammomatous
meningioma (Figure 4G, H), atypical meningioma (Fig-
u r e5 A - C )a n da n a p l a s t i cm e n i n g i o m a( F i g u r e5 D - I ) .
CXY2/ZC26-positive signals were detected broadly in
the tumor cell nuclei of each histological type (CXY2:
F i g u r e4 B ,D ,F ,H ,a n dF i g u r e5 B ,C ;Z C 2 6 :d a t an o t
shown), and overlapped with two meningioma molecular
markers, vimentin and EMA (Figure 5D-I). There was
no discernable difference between the intensity of stain-
ing among the different histological grades.
We performed immunohistochemical staining of other
types of brain and intracranial tumors as references
(Table 2). In glioblastoma multiforme, no ZIC-like sig-
nals were detected, with the exception of one of the
four cases that showed a weak signal for ZC26. Two out
of four hemangioblastomas stained weakly with CXY2.
A primitive neuroectodermal tumor and an atypical ter-
atoid rhabdoid tumor were CXY2-immunopositive.
ZIC proteins can be detected in normal arachnoid cells
To examine whether the presence of ZIC proteins in
meningioma relates to the tumor’s proposed histogen-
esis, we examined the localization of ZIC-like signals in
normal tissue adjacent to the tumor tissue. When we
examined the meningeal tissues, CXY2-positive signals
were detected in arachnoid cells that express vimentin,
but were not detected in the dura mater (Figure 6A, B,
E, F). ZIC4-positive signals were not detected in ara-
chnoid or dura mater cells (data not shown). By com-
parison, all three of the anti-ZIC antibodies gave clear
signals in the cell nuclei of cerebellar granule neurons
(Figure 6C, D, G, H), from which medulloblastomas are
considered to be derived.
We also explored the distribution of Zic proteins in
meningeal cells during development, using mouse as a
model. Mouse Zic proteins are present in meningeal cell
progenitors as early as when the primitive meninx tissue
appears (Figure 7A, [4]). CXY2-positive cells in the
meningeal layer were vimentin-positive along the course
of development (Figure 7E, F). After chondrogenic dif-
ferentiation of the outer layers had occurred (Figure 7B,
C, F, G), CXY2-positive signals were interposed between
the neuroepithelial cells and the chondrogenic region, as
delineated by CS56 staining (indicating the distribution
Figure 3 Specificity of the anti-ZIC antibodies.P r o t e i n
immunoblot analysis. N-terminally HA epitope-tagged ZIC proteins
were produced in 293T cells and were detected by CXY2, ZC26,
anti-ZIC4 and anti HA-tag antibodies.
Table 2 ZIC-like immunoreactivities in brain tumors
CXY2 ZC26 ZIC4
nuc_stain*
Grade I Meningioma ++ (12/22) ++ (2/22) - (22/22)
+ (7/22) + (14/22)
± (3/22) ± (6/22)
Grade II Meningioma** ++ (1/1) ++ (1/1) - (1/1)
Grade III Meningioma** ++ (1/1) + (1/1) - (1/1)
Medulloblastoma ++ (4/4) ++ (4/4) ++ (4/4)
Glioblastoma ± (1/4)
- (4/4) - (3/4) - (4/4)
Hemangioblastoma ± (2/4) ± (1/4)
- (2/4) - (3/4) - (4/4)
Primitive
neuroectodermal tumor
+ (1/1) + (1/1) - (1/1)
Atypical teratoid
rhabdoid tumor
+ (1/1) + (1/1) - (1/1)
Intensity of the staining: -, none; ±, low; +, medium; ++, high. *, Although
ZIC4 antibodies gave both nuclear and cytoplasmic staining, only the nuclear
staining (nuc_stain) were evaluated. **, these two specimens derive from the
same patient at different stages.
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were limited to the arachnoid layer. The CXY2-positive
signals were also detected in the mature arachnoid cells
(Figure 7D, H), similar to our observation in the human
adult meningeal membrane (Figure 6A, B, E, F).
Discussion
ZIC expression in meningioma and normal
meningeal cells
The distribution of ZIC-like immunopositive signals in
meningiomas may reflect the property of the arachnoid
cells from which meningiomas arise. Since Zic proteins
play an essential role in the proliferation of meningeal
cell progenitors [4], we consider it possible that ZIC
proteins are involved in the proliferation of meningioma
cells. This is consistent with our observation that ZIC1,
ZIC2 and ZIC5 mRNA levels are higher in meningiomas
than in normal brain tissues. We suggest that studies to
elucidate the involvement of ZIC genes in the menin-
gioma tumor cell proliferation would be beneficial.
Antibodies against EMA, vimentin and Ki-67 have
been used to provide histopathological differential diag-
noses of meningioma and to estimate its malignancy
grade [1]; however, no molecular marker that is specific
for meningiomas has been described to date. Although
additional studies in more cases of various brain tumors
Figure 4 Immunostaining of benign meningioma with CXY2 antibody. The representative immunostaining images for each histological
subtype. (A, B) Menigothelial meningioma. (C, D) Fibrous meningioma. (E, F) Transitional meningioma; characteristic whirling (black arrowheads)
are observed. (G, H) Psammomatous meningioma; some psammoma bodies are indicated by white arrowheads. (A, C, E, G) Hematoxylin and
eosin staining. (B, D, F, H) Immunostaining with CXY2 antibody. Scale bar, 100 μm.
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will be helpful for diagnoses in extraaxial brain tumors.
In terms of meningeal expression of ZIC genes, a pre-
vious in situ hybridization study [4] indicates that
mouse Zic1 and Zic2 are strongly expressed in the
embryonic meningeal cells and its precursors. Our study
confirms these results and clarifies that the expression
of Zic genes continues during development in the ara-
chnoid cell lineage in mouse. We detected immunoreac-
tive Zic/ZIC proteins in meningeal cells in both mouse
and human adult brains. Although the physiological role
of ZIC proteins in the adult meningeal cells has not
been clarified, ZIC proteins might be involved in the
maintenance of cell properties of differentiated ara-
chnoid cells, analogous to their role in meningeal cell
differentiation in mouse development.
Differential expression of human ZIC genes in tumors
A major finding of this study is the differential expres-
sion of members of the human ZIC gene family in var-
ious brain tumor types. RT-PCR analysis revealed that
ZIC4 expression is highly enhanced in medulloblastoma,
Figure 5 Detection of ZIC-like immunoreactivities in atypical and malignant meningioma.( A –C) Atypical meningioma with partially
“blastic changes”.( D –I) Anaplastic meningioma with geographic necrotic patterns. Each set of sections (A, B), (D, E), (F, G), and (H, I) is comprised
of neighboring sections. (C) is the higher magnification of the boxed region in (B). (A) Hematoxylin and eosin staining. (B, C, D, F, H, J)
Immunostaining with CXY2 antibody. (E, G) Immunostaining with anti-vimentin (VIM) antibody. (I, K) Immunostaining with anti-EMA antibody.
Thick scale bar, 1 mm; thin scale bar, 100 μm.
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Page 7 of 10Figure 6 Distribution of ZIC proteins in normal tissues. Human adult-derived normal tissues were examined. (A, B, E, F) Meningeal
membrane. (A, B, F) is comprised of neighboring sections. Image in (E) is a higher magnification of the boxed region in (A). Immunostaining
with CXY2 (A, E), CXY2/vimentin (F), and hematoxylin and eosin staining (B) are shown. ZIC-like immunoreactivities are indicated as brown
signals in (A, E, F). Vimentin-like signals are indicated by black in (F). Most Zic-like signals in cell nuclei are surrounded by the cytoplasmic
Vimentin-like signals. a, arachnoid layer; d, dura mater. Scale bar, 100 μm. (C, D, G, H) Cerebellum. Immunostaining with CXY2 (C), ZC26 (G), and
anti-ZIC4 (H), and hematoxylin and eosin staining (D) are shown. ZIC-like immunoreactivities are indicated as brown signals in (C, G, H). The
majority of the cell nuclei in the granule cell layer are commonly stained with the three anti-Zic antibodies. In (H), the arrowheads indicate the
cytoplasmic staining of the cells in Purkinje cell layer. The derivation of the cytoplasmic signals by the anti-ZIC4 antibody staining is unknown. gl,
granule cell layer of cerebellum; ml, molecular layer of cerebellum; pl, Purkinje cell layer. Scale bar, 100 μm.
Figure 7 Distribution of Zic proteins in mouse meningeal membrane. Mouse sections were derived from coronal sections through the
forebrain at embryonic day 12.5, E12.5 (A, E), embryonic day 14.5, E14.5 (B, C, F, G) or 12 weeks after birth, P12w (D, H). Images (A, E), (B, F) and
(C, G) indicate the same regions respectively. Image in (H) is a higher magnification of the boxed region in (D). Immunostaining with CXY2 (A, B,
D, H), CXY2/vimentin (E, F), and CXY2/CS56 (C), and differential interference contrast image (G) are shown. Zic signals are indicated by red in (A–
C, E, F), and brown in (D, H). The colour green indicates CS56 (C) and vimentin (E, F) immunoreactivities. In (C), the ZIC-like and CS56
immunoreactivities overlapped within the arachnoid layer that expresses vimentin; whereas, only CS56–positive signals were detected within the
chondrogenic area, between the two broken lines. The white line indicates the interface between meningeal tissue and cerebral cortex. CS56–
positive signals were detected in the region that forms the basal lamina (asterisks). In the adult mouse brain, Zic proteins were still produced in
the meningeal cells, as well as the lateral septal nucleus, medial septal nucleus, and diagonal band (D). The positive signals were detected in the
arachnoid and perivascular cells (H). a, arachnoid layer; ch, chondrogenic region (prospective temporal bone); ctx, cerebral cortex; db, diagonal
band; ls, lateral septal nucleus; ms, medial septal nucleus; v, vessel. Thick scale bar, 1 mm; thin scale bar, 100 μm.
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brain, while ZIC1, ZIC2 and ZIC5 are expressed both in
the meningioma and medulloblastoma. The results of
the immunoscreening are consistent with the RT-PCR
results in that ZIC4-like nuclear staining was almost
limited to the medulloblastoma cases. Although we
detected low amounts of ZIC4 transcript in one of the
three-meningioma cases, the immunoreactive ZIC4 pro-
tein level in this sample was below the limit of detection
(data not shown). The distinctive expression profile of
ZIC4 highlights its usefulness as a molecular marker for
brain tumor pathology.
Interestingly, in a cohort of patients with small cell
lung carcinoma, one of the most aggressive tumors
known, autoantibodies to ZIC2 are present in 28% of
patients, and the presence of these autoantibodies is
associated with less aggressive clinical parameters such
as a better response to initial therapy [14]. Autoantibo-
dies in small lung cell carcinoma patients show cross-
reactivity among ZIC1, ZIC2, and ZIC4 proteins [15],
suggesting that immunoreactivities of the autoantibodies
are directed primarily against the conserved zinc finger
domains of ZIC [16]. Furthermore, ZIC autoantibodies
have been detected in patients with both small cell lung
carcinoma and paraneoplastic neurological syndrome,
although it is not clear whether the immune response to
ZIC proteins is pathogenically related to the develop-
ment of the neurological syndrome [16]. In small cell
lung carcinoma, it is important that the expression of
ZIC proteins, and the usability of ZIC autoantibodies as
a diagnostic tool, are further clarified. Therefore, com-
prehensive studies that examine each of the five mem-
bers of the ZIC family proteins, and their corresponding
autoantibodies are required.
Our findings, together with those of previous studies
[8-10], demonstrate the importance of ZIC proteins in
clinical oncology. Future studies will require improved
ZIC protein- or anti-ZIC antibody-detection systems.
We suggest that the anti-ZIC antibodies and the full-
length ZIC1-5 expression vectors described in this study
will be useful for this purpose.
Conclusions
The main results can be summarized as follows:
1) ZIC1, ZIC2,a n dZIC5 mRNA levels are high in
meningiomas.
2) All ZIC genes are abundantly expressed in
medulloblastomas.
3) ZIC1 mRNA levels are higher in Grade II than in
Grade I meningiomas.
4) ZIC1/2/3/5-like immunopositive signals are
detected in most meningiomas irrespective of their his-
tological type.
5) ZIC1/2/3/5-like immunopositive signals are
detected in the arachnoid cell lineage.
6) ZIC1/2/3/5 and ZIC4-like immunopositive signals
are detected in both human cerebellar granule neurons
and medulloblastomas.
Additional file 1: Immunofluorescence staining of the NIH3T3 cells
producing HA-ZIC1-5 proteins. The expressed proteins and the
antibodies used for immunostaining are indicated at the side and top of
the panels, respectively. All of the human ZIC proteins were detected in
the cell nuclei.




ACTB: b actin; DAB: 3,3’-Diaminobenzidine; EMA: epithelial membrane
antigen; HA: hemaglutinin; Zic: Zinc finger protein of the cerebellum.
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